Symbol | Exchange | Currency |
|---|
Humanigen (HGEN) has entered into an arrangement with Clinigen Group (CLIGF) to implement a Managed Access Program for lenzilumab (LenzMAP)
By Samuel IndykInvesting.com – At 07:30BST, FTSE 100 Futures are trading flat at 7,055.In FX markets, GBP/USD is trading at 1.3601, EUR/GBP is trading at 0.8489. The US Dollar...
One of the world’s most feared activist investors is pushing the listed healthcare company Clinigen to explore options include a radical break-up.
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Buy | Strong Buy | Buy | Buy | Sell |
| Technical Indicators | Strong Buy | Neutral | Sell | Strong Buy | Strong Sell |
| Summary | Strong Buy | Buy | Neutral | Strong Buy | Strong Sell |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 48.73 | 48.87 | 48.13 | +0.41 | +0.84% | 93.01M | London | |||
| 110.82 | 111.40 | 110.06 | -0.06 | -0.05% | 32.55M | London | |||
| 82.30 | 83.30 | 75.70 | +5.00 | +6.47% | 3.53M | London | |||
| 355.00 | 358.80 | 352.00 | -1.20 | -0.34% | 23.65M | London | |||
| 48.96 | 50.15 | 47.04 | +2.62 | +5.65% | 3.74M | London | |||
| 2,046.00 | 2,098.00 | 1,996.00 | -28.0 | -1.35% | 61.07K | London | |||
| 1.38 | 1.38 | 1.38 | 0.00 | 0.00% | 115.75K | London | |||
| 434.80 | 437.95 | 432.25 | +0.05 | +0.01% | 19.56M | London | |||
| 313.00 | 314.00 | 310.00 | 0.00 | 0.00% | 1.24M | London | |||
| 149.50 | 155.50 | 149.40 | -6.10 | -3.92% | 7.71M | London | |||
| 1,460.40 | 1,503.40 | 1,457.20 | -30.6 | -2.05% | 799.37K | London | |||
| 202.00 | 206.00 | 200.00 | -0.50 | -0.25% | 488.43K | London | |||
| 1,422.50 | 1,431.00 | 1,416.50 | +3.00 | +0.21% | 368.64K | London | |||
| 1,438.50 | 1,459.00 | 1,438.50 | -11.50 | -0.79% | 1.70M | London | |||
| 99.50 | 99.50 | 99.50 | 0.00 | 0.00% | 0.00 | London |
Clinigen Group plc is a United Kingdom-based pharmaceutical and services company. The Company's principal activities include management, sale and distribution of pharmaceutical products, which have associated expiry dates. The Company operates through five segments: Clinigen Clinical Trial Services (CTS), which sources commercial medical products for use in clinical studies, including comparator drugs, adjuvant drugs and rescue therapies; Idis Managed Access (MA), which is engaged in the consultancy, development, management and implementation of managed access programs for biotechnology and pharmaceutical companies; Idis Global Access (GA), which offers ethical access to post approval and short-supply medicines; Clinigen Specialty Pharmaceuticals (SP), which manufactures and distributes its own and in-licensed specialist, hospital-only medicines around the world, and Link Healthcare, which distributes pharmaceutical products in South Africa, and the Asia and Pacific region.